title: Tumour-induced hypercalcaemia, resistant to systemic anti-hypercalcaemic and chemo-endocrine treatments, but responding to radiotherapy in a breast cancer patient.
authors.affiliation: Department of Medical Oncology, Institute for Oncology and Radiology of Serbia, Yygoslavia.
authors.forename: Z
authors.initials: Z
authors.lastname: Nesković-Konstantinović
authors.forename: S
authors.initials: S
authors.lastname: Susnjar
authors.forename: S
authors.initials: S
authors.lastname: Vasović
authors.forename: N
authors.initials: N
authors.lastname: Borojević
authors.forename: L
authors.initials: L
authors.lastname: Mitrović
authors.forename: L
authors.initials: L
authors.lastname: Radosević-Jelić
authors.forename: S
authors.initials: S
authors.lastname: Radulović
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000532:radiotherapy; D002116:Calcitonin / Q000627:therapeutic use; D018275:Carcinoma, Lobular / Q000150:complications* / Q000188:drug therapy / Q000532:radiotherapy; D005260:Female; D006801:Humans; D006934:Hypercalcemia / Q000188:drug therapy / Q000209:etiology* / Q000532:radiotherapy; D008875:Middle Aged; D010166:Palliative Care; D010257:Paraneoplastic Syndromes / Q000188:drug therapy / Q000209:etiology* / Q000532:radiotherapy; D011879:Radiotherapy Dosage
chemical_list: D018931:Antineoplastic Agents, Hormonal; C028815:salmon calcitonin; D002116:Calcitonin